Logo-bi
Bioimpacts. 2020;10(4): 209-215. doi: 10.34172/bi.2020.27
PMID: 32983936        PMCID: PMC7502909

Original Research

Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial

Khalil Ansarin 1,2 ORCID, Ramin Tolouian 3, Mohammadreza Ardalan 4 * ORCID, Ali Taghizadieh 2,5, Mojtaba Varshochi 6, Soheil Teimouri 5, Tahere Vaezi 5, Hamed Valizadeh 2,5, Parviz Saleh 4, Saeid Safiri 7,8 ORCID, Kenneth R. Chapman 9 ORCID

Cited by CrossRef: 89

1- Gholami A, Minai-Tehrani D, Farewell A, Eriksson L. Discovery of novel inhibitors for Pseudomonas aeruginosa lipase enzyme from in silico and in vitro studies . Journal of Biomolecular Structure and Dynamics. 2024;42(5):2197 [Crossref]
2- Rahmani D, Jafari A, Kesharwani P, Sahebkar A. Molecular targets in SARS-CoV-2 infection: An update on repurposed drug candidates. Pathology - Research and Practice. 2024;263:155589 [Crossref]
3- Perico L, Benigni A, Remuzzi G. Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. 2021;30(2):252 [Crossref]
4- Das K, Patil A, Goren A, Cockerell C, Goldust M. Androgens and COVID‐19. J of Cosmetic Dermatology. 2022;21(8):3176 [Crossref]
5- Mikhaylov E, Lyubimtseva T, Vakhrushev A, Stepanov D, Lebedev D, Vasilieva E, Konradi A, Shlyakhto E, Tharmalingam J. Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study. Interdisciplinary Perspectives on Infectious Diseases. 2022;2022:1 [Crossref]
6- Perico L, Benigni A, Casiraghi F, Ng L, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17(1):46 [Crossref]
7- Thabet R, Massadeh N, Badarna O, Al-Momani O. Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics. J Int Med Res. 2023;51(1) [Crossref]
8- Onwudiwe O, Weli H, Shaanu T, Akata N, Ebong I. Pharmacological treatment of COVID-19: an update. 2020;4 [Crossref]
9- Mahmoud I, Jarrar Y. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges. Mol Biol Rep. 2021;48(5):4667 [Crossref]
10- Karahalil B, Elkama A. COVID-19: Are Experimental Drugs a Cure or Cause?. CDS. 2022;17(2):83 [Crossref]
11- Honarmand K, Penn J, Agarwal A, Siemieniuk R, Brignardello-Petersen R, Bartoszko J, Zeraatkar D, Agoritsas T, Burns K, Fernando S, Foroutan F, Ge L, Lamontagne F, Jimenez-Mora M, Murthy S, Yepes-Nuñez J, Vandvik P, Ye Z, Rochwerg B. Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. Journal of Clinical Epidemiology. 2021;139:68 [Crossref]
12- Wettstein L, Kirchhoff F, Münch J. The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment. IJMS. 2022;23(3):1351 [Crossref]
13- Panahi Y, Gorabi A, Talaei S, Beiraghdar F, Akbarzadeh A, Tarhriz V, Mellatyar H. An overview on the treatments and prevention against COVID-19. Virol J. 2023;20(1) [Crossref]
14- Sgrignani J, Cavalli A. Computational Identification of a Putative Allosteric Binding Pocket in TMPRSS2. Front Mol Biosci. 2021;8 [Crossref]
15- Mohammadi M, Khafaee Pour Khamseh A, Varpaei H. Invasive Airway "Intubation" in COVID-19 Patients; Statistics, Causes, and Recommendations: A Review Article. Anesth Pain Med. 2021;11(3) [Crossref]
16- Kumawat P, Agarwal L, Sharma K. An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies. Curr Microbiol. 2024;81(7) [Crossref]
17- Zhao X, Luo S, Huang K, Xiong D, Zhang J, Duan L. Targeting mechanism for SARS-CoV-2 in silico: interaction and key groups of TMPRSS2 toward four potential drugs. Nanoscale. 2021;13(45):19218 [Crossref]
18- Alegría-Arcos M, Barbosa T, Sepúlveda F, Combariza G, González J, Gil C, Martínez A, Ramírez D. Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19. Front Pharmacol. 2022;13 [Crossref]
19- Eslami-Ghayour A, Nazari S, Keramat F, Shahbazi F, Eslami-Ghayour A. Evaluación de la eficacia de la N-acetilcisteína y la bromhexina en comparación con la atención estándar en la prevención de la hospitalización de pacientes ambulatorios con COVID-19: un ensayo clínico aleatorizado doble ciego. Revista Clínica Española. 2024;224(2):86 [Crossref]
20- Gorący A, Rosik J, Szostak B, Ustianowski Ł, Ustianowska K, Gorący J. Human Cell Organelles in SARS-CoV-2 Infection: An Up-to-Date Overview. Viruses. 2022;14(5):1092 [Crossref]
21- Ortega J, Zambrano J, Jastrzebska B, Liprandi F, Rangel H, Pujol F. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies. Intervirology. 2020;63(1-6):2 [Crossref]
22- Dasgupta A, Gangai S, Narayan R, Kapoor S. Mapping the Lipid Signatures in COVID-19 Infection: Diagnostic and Therapeutic Solutions. J Med Chem. 2023;66(21):14411 [Crossref]
23- Niknam Z, Jafari A, Golchin A, Danesh Pouya F, Nemati M, Rezaei-Tavirani M, Rasmi Y. Potential therapeutic options for COVID-19: an update on current evidence. Eur J Med Res. 2022;27(1) [Crossref]
24- Mitev V. Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib. PHAR. 2023;70(4):1177 [Crossref]
25- Mohseni M, Ameri H, Arab-Zozani M. Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview. Front Med. 2022;9 [Crossref]
26- Lisnund S, Blay V, Muamkhunthod P, Thunyanon K, Pansalee J, Monkrathok J, Maneechote P, Chansaenpak K, Pinyou P. Electrodeposition of Cobalt Oxides on Carbon Nanotubes for Sensitive Bromhexine Sensing. Molecules. 2022;27(13):4078 [Crossref]
27- Torshin I, Gromova O, Chuchalin A, Zhuravlev Y. Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy. Farmakoèkonomika. 2021;14(2):191 [Crossref]
28- Cani M, Epistolio S, Dazio G, Modesti M, Salfi G, Pedrani M, Isella L, Gillessen S, Vogl U, Tortola L, Treglia G, Buttigliero C, Frattini M, Pereira Mestre R. Antiandrogens as Therapies for COVID-19: A Systematic Review. Cancers. 2024;16(2):298 [Crossref]
29- Ben-Zuk N, Dechtman I, Henn I, Weiss L, Afriat A, Krasner E, Gal Y. Potential Prophylactic Treatments for COVID-19. Viruses. 2021;13(7):1292 [Crossref]
30- Garbern S, Relan P, O’Reilly G, Bills C, Schultz M, Trehan I, Kivlehan S, Becker T. A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries. J Glob Health. 2022;12 [Crossref]
31- Vila Méndez M, Antón Sanz C, Cárdenas García A, Bravo Malo A, Torres Martínez F, Martín Moros J, Real Torrijos M, Vendrell Covisa J, Guzmán Sierra O, Molina Barcena V, Viejo Pinero N, Fernández Díaz C, Arroyo Burguillo P, Blanco Gallego A, Guirao Sánchez C, Montilla Bernabé A, Villanueva Morán M, Juárez Antón S, Fernández Rodríguez Á, Somoza Calvo M, Cerrada E, Pérez Mañas G, Sánchez Calso A, Vallejo Somohano F, Cauqui Díaz C, Viñas Fernández G, Molina París J, González Godoy M, Lumbreras García G, Rosado Martín J, Rodríguez Hernández A, López Antúñez S, Vázquez Perfecto G, Marcello Andrés M, Puente García N, Gil C, Martínez A, Soler López B. Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial. JCM. 2022;12(1):142 [Crossref]
32- Kumar S, Priya N, Nithya S, Kannan P, Jain N, Kumar D, Magesh R, Younes S, Zayed H, Doss C. A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. 3 Biotech. 2021;11(4) [Crossref]
33- Ku K, Shin H, Kim H, Kim B, Kim S, Kim C. Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2. J Microbiol Biotechnol. 2020;30(12):1843 [Crossref]
34- Ouni L, Ramazani A. In Silico Screening of Some Anti-Cancer Drugs Against the Main Protease of COVID-19 Using Molecular Docking. LOC. 2023;20(1):77 [Crossref]
35- Luan B, Huynh T, Cheng X, Lan G, Wang H. Targeting Proteases for Treating COVID-19. J Proteome Res. 2020;19(11):4316 [Crossref]
36- Wannigama D, Hurst C, Phattharapornjaroen P, Hongsing P, Sirichumroonwit N, Chanpiwat K, Rad S.M. A, Storer R, Ounjai P, Kanthawee P, Ngamwongsatit N, Kupwiwat R, Kupwiwat C, Brimson J, Devanga Ragupathi N, Charuluxananan S, Leelahavanichkul A, Kanjanabuch T, Higgins P, Badavath V, Amarasiri M, Verhasselt V, Kicic A, Chatsuwan T, Pirzada K, Jalali F, Reiersen A, Abe S, Ishikawa H, Tanasatitchai C, Amphol S, Nantawong L, Sangchan P, Sinkajarern V, Phoonakh T, Utenpattanun P, Sithu Shein A, Vitoonpong T, Chongthavonsatit N, Mankong Y, Chaichana P, Yaithet J, Pongprajak D, Traimuangpak S, Saksirisampant G, Lamloeskittinon P, Hamdy A, Kosasih S, Luk-in S. Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial. eClinicalMedicine. 2024;70:102517 [Crossref]
37- Tao K, Tzou P, Nouhin J, Bonilla H, Jagannathan P, Shafer R. SARS-CoV-2 Antiviral Therapy. Clin Microbiol Rev. 2021;34(4) [Crossref]
38- Hörnich B, Großkopf A, Schlagowski S, Tenbusch M, Kleine-Weber H, Neipel F, Stahl-Hennig C, Hahn A, Gallagher T. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation. J Virol. 2021;95(9) [Crossref]
39- Eslami Ghayour A, Nazari S, Keramat F, Shahbazi F, Eslami-Ghayour A. Evaluation of the efficacy of N-acetylcysteine and bromhexine compared with standard care in preventing hospitalization of outpatients with COVID-19: a double blind randomized clinical trial. Revista Clínica Española (English Edition). 2024;224(2):86 [Crossref]
40- Shrimp J, Kales S, Sanderson P, Simeonov A, Shen M, Hall M. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19. ACS Pharmacol Transl Sci. 2020;3(5):997 [Crossref]
41- Mareev V, Orlova Y, Plisyk A, Pavlikova E, Matskeplishvili S, Akopyan Z, Seredenina E, Potapenko A, Agapov M, Asratyan D, Dyachuk L, Samokhodskaya L, Mershina Е, Sinitsyn V, Pakhomov P, Bulanova M, Fuks A, Mareev Y, Begrambekova Y, Kamalov А. Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT). Kardiologiia. 2020;60(11):4 [Crossref]
42- Mantzourani C, Vasilakaki S, Gerogianni V, Kokotos G. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19. Expert Opinion on Drug Discovery. 2022;17(3):231 [Crossref]
43- Zhang C, Jin H, Wen Y, Yin G. Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Front Public Health. 2021;9 [Crossref]
44- Law M, Ho R, Law K, Cheung C. Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. WJH. 2021;13(12):1850 [Crossref]
45- Kiaei A, Salari N, Boush M, Mansouri K, Hosseinian-Far A, Ghasemi H, Mohammadi M. Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. Life. 2022;12(9):1456 [Crossref]
46- Wambier C, McCoy J, Goren A. Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals. Journal of the American Academy of Dermatology. 2020;83(6):e401 [Crossref]
47- Banerjee S, Wang X, Du S, Zhu C, Jia Y, Wang Y, Cai Q. Comprehensive role of SARS‐CoV‐2 spike glycoprotein in regulating host signaling pathway. Journal of Medical Virology. 2022;94(9):4071 [Crossref]
48- Li J, Jia H, Tian M, Wu N, Yang X, Qi J, Ren W, Li F, Bian H. SARS-CoV-2 and Emerging Variants: Unmasking Structure, Function, Infection, and Immune Escape Mechanisms. Front Cell Infect Microbiol. 2022;12 [Crossref]
49- Wang T, Zhai Y, Xue H, Zhou W, Ding Y, Nie H. Regulation of Epithelial Sodium Transport by SARS-CoV-2 Is Closely Related with Fibrinolytic System-Associated Proteins. Biomolecules. 2023;13(4):578 [Crossref]
50- Naveja J, Madariaga-Mazón A, Flores-Murrieta F, Granados-Montiel J, Maradiaga-Ceceña M, Alaniz V, Maldonado-Rodriguez M, García-Morales J, Senosiain-Peláez J, Martinez-Mayorga K. Union is strength: antiviral and anti-inflammatory drugs for COVID-19. Drug Discovery Today. 2021;26(1):229 [Crossref]
51- Noori M, Nejadghaderi S, Sullman M, Carson-Chahhoud K, Ardalan M, Kolahi A, Safiri S. How SARS-CoV-2 might affect potassium balance via impairing epithelial sodium channels?. Mol Biol Rep. 2021;48(9):6655 [Crossref]
52- Rahbar Saadat Y, Hosseiniyan Khatibi S, Zununi Vahed S, Ardalan M. Host Serine Proteases: A Potential Targeted Therapy for COVID-19 and Influenza. Front Mol Biosci. 2021;8 [Crossref]
53- Camelo S, Latil M, Agus S, Dioh W, Veillet S, Lafont R, Dilda P. A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality. Emerging Microbes & Infections. 2021;10(1):2256 [Crossref]
54- Varshochi M, Shahi M, Rahimzadeh M, Amini H, Mohammadzadeh R. Efficacy and Safety of Novel Herbal Tablets in COVID-19 Patients in Hospital Stay Days, ICU Admission and Mortality Rate Thereof: An Ppen-Label, Single-Blind Randomized Clinical Trial. Jundishapur J Nat Pharm Prod. 2021;17(2) [Crossref]
55- Yan W, Zheng Y, Zeng X, He B, Cheng W. Structural biology of SARS-CoV-2: open the door for novel therapies. Sig Transduct Target Ther. 2022;7(1) [Crossref]
56- Juul S, Nielsen E, Feinberg J, Siddiqui F, Jørgensen C, Barot E, Holgersson J, Nielsen N, Bentzer P, Veroniki A, Thabane L, Bu F, Klingenberg S, Gluud C, Jakobsen J, Bonovas S. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS ONE. 2021;16(3):e0248132 [Crossref]
57- Bahadoram S, Keikhaei B, Bahadoram M, Mahmoudian-Sani M, Hassanzadeh S, Saeedi-Boroujeni A, Alikhani K. Bromhexine is a potential drug for COVID-19; From hypothesis to clinical trials. Problems of Virology. 2022;67(2):126 [Crossref]
58- Ahmadi E, Afrooghe A, Soltani Z, Elahi M, Shayan M, Ohadi M, Dehpour A. Beyond the lungs: Exploring diverse applications of bromhexine and ambroxol. Life Sciences. 2024;353:122909 [Crossref]
59- Ninham B, Reines B, Battye M, Thomas P. Pulmonary surfactant and COVID-19: A new synthesis. QRB Discovery. 2022;3 [Crossref]
60- Welte T, Ambrose L, Sibbring G, Sheikh S, Müllerová H, Sabir I. Current evidence for COVID-19 therapies: a systematic literature review. Eur Respir Rev. 2021;30(159):200384 [Crossref]
61- Ahmadian E, Hosseiniyan Khatibi S, Razi Soofiyani S, Abediazar S, Shoja M, Ardalan M, Zununi Vahed S. Covid‐19 and kidney injury: Pathophysiology and molecular mechanisms. Reviews in Medical Virology. 2021;31(3) [Crossref]
62- Sagawa T, Inoue K, Takano H. Use of protease inhibitors for the prevention of COVID-19. Preventive Medicine. 2020;141:106280 [Crossref]
63- Tolouian R, Mulla Z, Jamaati H, Babamahmoodi A, Marjani M, Eskandari R, Dastan F. Effect of bromhexine in hospitalized patients with COVID-19. Journal of Investigative Medicine. 2023;71(7):691 [Crossref]
64- Pillay T, Strydom M. The potential role of bromhexine in COVID-19 – Has a possible new candidate been “coughed” up?. South African General Practitioner. 2021;2(5):164 [Crossref]
65- Duan X, Lacko L, Chen S. Druggable targets and therapeutic development for COVID-19. Front Chem. 2022;10 [Crossref]
66- Shahdad A, Fadaee Aghdam N, Goli S, Binesh E, Nourian J, Khajeh M. Effect of transcutaneous electrical nerve stimulation of acupoints on respiratory outcomes of COVID‐19 patients with moderate pulmonary involvement: A parallel randomized clinical trial. Health Science Reports. 2023;6(7) [Crossref]
67- Arumugam G, Damodharan K, Doble M, Thennarasu S. Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity. Mol Biomed. 2022;3(1) [Crossref]
68- Fratta Pasini A, Stranieri C, Cominacini L, Mozzini C. Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications. Antioxidants. 2021;10(2):272 [Crossref]
69- Richards G, Wentzel A, Miller R, van Zyl Smit R. Post-Acute COVID-19 Sequelae – ‘COVID Long Hauler’. WJCM. 2021;3(2):117 [Crossref]
70- Mekky R, Elemam N, Eltahtawy O, Zeinelabdeen Y, Youness R. Evaluating Risk: Benefit Ratio of Fat-Soluble Vitamin Supplementation to SARS-CoV-2-Infected Autoimmune and Cancer Patients: Do Vitamin–Drug Interactions Exist?. Life. 2022;12(10):1654 [Crossref]
71- Mateus D, Sebastião A, Carrascal M, Carmo A, Matos A, Cruz M. Crosstalk between estrogen, dendritic cells, and SARS‐CoV‐2 infection. Reviews in Medical Virology. 2022;32(3) [Crossref]
72- Hamidi F, Hamishehkar H, Azari Markid P, Sarbakhsh P. Identifying factors related to mortality of hospitalized COVID-19 patients using machine learning methods. Heliyon. 2024;10(15):e35561 [Crossref]
73- Wambier C, Mehta N, Goren A, Cadegiani F. COVID‐19, androgens, and androgenic alopecia. Dermatological Reviews. 2021;2(3):146 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge